关于：血液透析患者骨质疏松症患者接受一年罗莫索单抗治疗后再接受一年地诺单抗治疗的观察性研究。 - Suppr

Suppr

超能文献

RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

作者信息

Pazianas Michael

机构信息

Institute of Musculoskeletal Sciences, Oxford University, Oxford, OX3 7LD, UK.

出版信息

Calcif Tissue Int. 2023 May;112(5):628-629. doi: 10.1007/s00223-022-01055-y. Epub 2022 Dec 27.

DOI:10.1007/s00223-022-01055-y

PMID:36574024

Abstract

摘要

相似文献

RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Calcif Tissue Int. 2023 May;112(5):628-629. doi: 10.1007/s00223-022-01055-y. Epub 2022 Dec 27.

Denosumab versus romosozumab for postmenopausal osteoporosis treatment.

Sci Rep. 2021 Jun 3;11(1):11801. doi: 10.1038/s41598-021-91248-6.

One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Calcif Tissue Int. 2023 Jan;112(1):34-44. doi: 10.1007/s00223-022-01031-6. Epub 2022 Oct 26.

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

Osteoporos Int. 2019 Dec;30(12):2437-2448. doi: 10.1007/s00198-019-05146-9. Epub 2019 Oct 18.

Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment.

Osteoporos Int. 2022 Jun;33(6):1265-1273. doi: 10.1007/s00198-021-06261-2. Epub 2022 Jan 21.

Comment on One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Calcif Tissue Int. 2023 Aug;113(2):254-255. doi: 10.1007/s00223-023-01084-1. Epub 2023 Apr 19.

Treatment of glucocorticoid-induced osteoporosis with concurrent denosumab and romosozumab: a case report.

Osteoporos Int. 2024 Nov;35(11):2061-2068. doi: 10.1007/s00198-024-07243-w. Epub 2024 Sep 17.

Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.

Osteoporos Int. 2022 Aug;33(8):1807-1813. doi: 10.1007/s00198-022-06386-y. Epub 2022 Apr 1.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.

Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z.

引用本文的文献

Comment on One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Calcif Tissue Int. 2023 Aug;113(2):254-255. doi: 10.1007/s00223-023-01084-1. Epub 2023 Apr 19.

本文引用的文献

One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.

Calcif Tissue Int. 2023 Jan;112(1):34-44. doi: 10.1007/s00223-022-01031-6. Epub 2022 Oct 26.

Sclerostin Protects Against Vascular Calcification Development in Mice.

J Bone Miner Res. 2022 Apr;37(4):687-699. doi: 10.1002/jbmr.4503. Epub 2022 Feb 15.

Bones, heart and the new anabolic agent romosozumab.

Postgrad Med J. 2019 Oct;95(1128):521-523. doi: 10.1136/postgradmedj-2019-136699. Epub 2019 Aug 17.

Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!

Nephrol Dial Transplant. 2019 Mar 1;34(3):408-414. doi: 10.1093/ndt/gfy129.

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.

Nephrol Dial Transplant. 2012 Jan;27(1):226-30. doi: 10.1093/ndt/gfr270. Epub 2011 May 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验